Published in Ann Rheum Dis on September 01, 1990
Fibrocyte activation in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.68
Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis (2000) 1.53
Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum (2011) 1.49
Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis (1992) 1.36
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2003) 1.05
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.05
Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther (2009) 1.01
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis (1995) 1.00
Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis (1998) 0.98
Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis (1992) 0.97
Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling. Physiol Genomics (2007) 0.97
The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol (2000) 0.97
Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol (1994) 0.97
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol (1998) 0.96
Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging (2012) 0.94
Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities. Clin Rheumatol (1998) 0.86
Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients. BMC Musculoskelet Disord (2015) 0.82
Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice. Arthritis Rheumatol (2014) 0.81
CD146(+) mesenchymal stem cells display greater therapeutic potential than CD146(-) cells for treating collagen-induced arthritis in mice. Stem Cell Res Ther (2016) 0.79
Periarticular bone loss in antigen-induced arthritis. Arthritis Rheum (2013) 0.79
Optimized "in vitro" culture conditions for human rheumatoid arthritis synovial fibroblasts. Mediators Inflamm (2014) 0.78
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis. Arthritis Res Ther (2014) 0.78
GADD45γ regulates TNF-α and IL-6 synthesis in THP-1 cells. Inflamm Res (2012) 0.76
Inhibitory effects of EGb761 on the expression of matrix metalloproteinases (MMPs) and cartilage matrix destruction. Cell Stress Chaperones (2015) 0.75
Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices. EXCLI J (2012) 0.75
Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2015) 0.75
Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis. Biomed Res Int (2014) 0.75
Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion. RMD Open (2017) 0.75
Inflammatory genes TNFα and IL6 display no signs of increased H3K4me3 in circulating monocytes from untreated rheumatoid arthritis patients. Genes Immun (2017) 0.75
[Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. Wien Med Wochenschr (2003) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 8.77
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20
Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet (1981) 6.62
Stimulation of neutrophils by tumor necrosis factor. J Immunol (1986) 5.72
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A (1986) 5.03
Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med (1986) 4.99
Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol (1987) 4.75
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun (1986) 2.27
Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol (1985) 2.02
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61
Possible requirement of internalization in the mechanism of in vitro cytotoxicity in tumor necrosis serum. Cancer Res (1981) 1.30
Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum (1986) 1.30
Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol (1987) 1.17
Interferon-induced enzymatic activities and their role in the antriviral state. Cell (1979) 3.22
Inhibition of initiation of protein synthesis by 7-methylguanosine-5'-monophosphate. Proc Natl Acad Sci U S A (1976) 3.14
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
Interferon action may be mediated by activation of a nuclease by pppA2'p5'A2'p5'A. Nature (1978) 2.59
Evidence that types I and II interferons have different receptors. Nature (1981) 2.44
Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem (1979) 2.43
The release of platelet-activating factor from human endothelial cells in culture. J Immunol (1983) 2.41
Inhibition of protein synthesis in reticulocytes by antibiotics. I. Effects on polysomes. Biochim Biophys Acta (1966) 2.31
Reiteration frequency of haemoglobin genes in the duck. Nat New Biol (1972) 2.20
Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem (1985) 2.18
Further evidence of transcriptional and translational control of histone messenger RNA during the HeLa S3 cycle. Cell (1975) 2.16
Inhibition of protein synthesis in reticulocytes by antibiotics. II. The site of action of cycloheximide, streptovitacin A and pactamycin. Biochim Biophys Acta (1966) 2.12
Evidence for role of m7G5'-phosphate group in recognition of eukaryotic mRNA by initiation factor IF-M3. Nature (1976) 2.09
Allelic antigenic factor Inv(a) of the light chains of human immunoglobulins: chemical basis. Science (1966) 2.03
Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol (1986) 2.00
Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med (1987) 1.95
Inhibition of mRNA binding to ribosomes by localized activation of dsRNA-dependent protein kinase. Nature (1984) 1.91
The active form of tumor necrosis factor is a trimer. J Biol Chem (1987) 1.86
The AU-rich sequences in the 3' untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J Exp Med (1991) 1.84
Diagnostic therapeutic flow-charts for low back pain patients: the Italian clinical guidelines. Eura Medicophys (2006) 1.77
Synthesis of (2'-5')oligoadenylate and activation of an endoribonuclease in interferon-treated HeLa cells infected with reovirus. J Virol (1982) 1.77
Mechanisms of antiviral action of interferon. Interferon (1983) 1.76
The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med (1996) 1.72
Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev (2000) 1.70
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell Mol Med (2009) 1.58
Mechanism for discrimination between viral and host mRNA in interferon-treated cells. Proc Natl Acad Sci U S A (1979) 1.57
Retracted Loss of (2'-5')oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections. Proc Natl Acad Sci U S A (1987) 1.57
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol (2001) 1.57
Absence of messenger RNA for beta globin chain in beta(0) thalassaemia. Nature (1974) 1.55
Antibody-induced redistribution of Heymann antigen on the surface of cultured glomerular visceral epithelial cells: possible role in the pathogenesis of Heymann glomerulonephritis. J Immunol (1985) 1.52
Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem (1988) 1.52
Messenger RNA for globin in the postribosomal supernatant of rabbit reticulocytes. Proc Natl Acad Sci U S A (1972) 1.51
Phosphorylation of initiation factor eIF-2 alpha, binding of mRNA to 48 S complexes, and its reutilization in initiation of protein synthesis. J Biol Chem (1983) 1.50
HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest (1998) 1.49
Synthesis of 2'5'-oligo(A) in extracts of interferon-treated HeLa cells. J Biol Chem (1979) 1.49
Regulation of haemoglobin synthesis at the polysome level. J Mol Biol (1966) 1.47
Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon. J Biol Chem (1982) 1.46
Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol (1987) 1.46
Inhibition of protein synthesis by Cl-. J Biol Chem (1977) 1.44
Inhibition of protein synthesis in reovirus-infected HeLa cells with elevated levels of interferon-induced protein kinase activity. J Biol Chem (1982) 1.44
A simple and fast method to extract RNA from tissue culture cells. Biotechniques (1990) 1.43
Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors. J Biol Chem (1986) 1.40
5'-Terminal 7-methylguanosine and mRNA function: influence of potassium concentration on translation in vitro. Proc Natl Acad Sci U S A (1977) 1.35
Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proc Natl Acad Sci U S A (1992) 1.34
Inhibition of HeLa cell messenger RNA translation by 7-methylguanosine 5'-monophosphate. J Biol Chem (1976) 1.32
Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem (1991) 1.31
Mechanisms of action of human interferons. Induction of 2'5'-oligo(A) polymerase. J Biol Chem (1980) 1.31
A relation between inhibition of protein synthesis and conformation of 5'-phosphorylated 7-methylguanosine derivatives. J Mol Biol (1977) 1.31
Different mechanisms for activation of gene transcription by interferons alpha and gamma. Virology (1985) 1.29
A cell free system from HeLa cells active in initiation of protein synthesis. Biochemistry (1975) 1.28
Isolation of messenger RNA from polysomes by chromatography on oligo(dT)-cellulose. Anal Biochem (1975) 1.28
Unusual base-pairing of newly synthesized DNA in HeLa cells. J Mol Biol (1979) 1.28
Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages. J Virol (1989) 1.28
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol (1981) 1.27
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Maternal vascular prostacyclin activity in pre-eclampsia. Lancet (1980) 1.24
Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest (1984) 1.24
Degradation of unstable interleukin-1 alpha mRNA in a rabbit reticulocyte cell-free system. Localization of an instability determinant to a cluster of AUUUA motifs. J Biol Chem (1994) 1.22
A study of immunoglobulin structure. I. The fingerprinting of aminoethylated Bence-Jones proteins. Biochim Biophys Acta (1965) 1.22
Isolation of duck haemoglobin messenger RNA and its translation by rabbit reticulocyte cell free system. Nat New Biol (1972) 1.21
Translation of messenger RNA for histones from HeLa cells by a cell-free extract from mouse ascites tumor. Proc Natl Acad Sci U S A (1972) 1.21
Metabolic stability of 2' 5'oligo (A) and activity of 2' 5'oligo (A)-dependent endonuclease in extracts of interferon-treated and control HeLa cells. Nucleic Acids Res (1979) 1.20
Formation of immune deposits and disease. Lab Invest (1986) 1.20
Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. J Immunol (1987) 1.20
Presence of 2',5'-oligo(A) and of enzymes that synthesize, bind, and degrade 2',5'-oligo(A) in HeLa cell nuclei. J Biol Chem (1982) 1.19
Duck hemoglobin messenger RNA contains a polynucleotide sequence rich in adenylic acid. J Mol Biol (1972) 1.19
Increased levels of (2'-5')oligo(A) polymerase activity in human lymphoblastoid cells treated with glucocorticoids. Proc Natl Acad Sci U S A (1980) 1.19
Activation of hemin-regulated initiation factor-2 kinase in heat-shocked HeLa cells. J Biol Chem (1986) 1.19
Role of soluble mediators in angiogenesis. Eur J Cancer (1996) 1.17
Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med (1994) 1.17
Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int (2001) 1.17
Tumor necrosis factor increases stability of interleukin-1 mRNA by activating protein kinase C. J Biol Chem (1993) 1.17
Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol (1987) 1.17
Estimation of light-chain gene reiteration of mouse immunoglobulin by DNA-RNA hybridization. Proc Natl Acad Sci U S A (1973) 1.16
Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost (2007) 1.16
Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol (1985) 1.16
Assembly of membrane-bound polyribosomes. Nat New Biol (1971) 1.15
Origin of structural variation in Bence Jones proteins. J Mol Biol (1966) 1.14
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol (2000) 1.14
The glucocorticoid dexamethasone inhibits synthesis of interferon by decreasing the level of its mRNA. J Biol Chem (1988) 1.13
Virus-specific effects of interferon in embryonal carcinoma cells. Nature (1980) 1.13
Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int (1994) 1.12
Inhibition of protein synthesis by double-stranded RNA and phosphorylation of initiation factor, eIF-2. J Biol Chem (1978) 1.11
Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol (1998) 1.11
Activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells by 2'-O-methylated poly (inosinic acid) . poly(cytidylic acid), Correlations with interferon-inducing activity. J Biol Chem (1980) 1.11
Potential role of platelet-activating factor in renal pathophysiology. Kidney Int (1986) 1.09
Cleavage of nascent reovirus mRNA by localized activation of the 2'-5'-oligoadenylate-dependent endoribonuclease. J Virol (1984) 1.09
Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med (1997) 1.09
Cell-free translation of maternal messenger RNA from sea urchin eggs. Proc Natl Acad Sci U S A (1973) 1.09
Role of ribosomal subunits in protein synthesis in mammalian cells. Proc Natl Acad Sci U S A (1968) 1.09
Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol (1981) 1.08
Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol (1999) 1.08
Endothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia. Int J Immunopathol Pharmacol (2012) 1.07
Protection from tumor necrosis factor cytotoxicity by protease inhibitors. Cell Immunol (1987) 1.07
Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. J Exp Med (1988) 1.07
Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci U S A (1983) 1.07